Trial · NCT01667081
Results by group63
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 63
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Viral Relapse | GZR 100 mg + EBR 50 mg +/- RBV | NA | Inter-Quartile Range NA to NA | Months | |
| Time to Viral Relapse | Other GZR Regimen | NA | Inter-Quartile Range NA to NA | Months | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/- RBV: NS3 RASs | Failure | 22 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/- RBV: NS5A RASs | Failure | 25 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/-RBV: Both NS3 and NS5A RASs | Failure | 18 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | GZR + Pegylated Interferon/Ribavirin (PR): NS3 RASs | Failure | 11 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/- RBV: NS3 RASs | 24 weeks post failure | 10 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/- RBV: NS5A RASs | 24 weeks post failure | 25 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/-RBV: Both NS3 and NS5A RASs | 24 weeks post failure | 8 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | GZR + Pegylated Interferon/Ribavirin (PR): NS3 RASs | 24 weeks post failure | 2 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/- RBV: NS3 RASs | 48 weeks post failure | 6 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/- RBV: NS5A RASs | 48 weeks post failure | 22 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/-RBV: Both NS3 and NS5A RASs | 48 weeks post failure | 4 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | GZR + Pegylated Interferon/Ribavirin (PR): NS3 RASs | 48 weeks post failure | 2 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/- RBV: NS3 RASs | 96 weeks post failure | 4 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/- RBV: NS5A RASs | 96 weeks post failure | 15 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/-RBV: Both NS3 and NS5A RASs | 96 weeks post failure | 3 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | GZR + Pegylated Interferon/Ribavirin (PR): NS3 RASs | 96 weeks post failure | 1 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/- RBV: NS3 RASs | ≥144 weeks post failure | 2 | Participants | |
| Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections | EBR/GZR +/- RBV: NS5A RASs | ≥144 weeks post failure | 11 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01667081/results